A PHASE 3 MULTICENTER RANDOMIZED OPEN-LABEL STUDY OF IFINATAMAB DERUXTECAN (I-DXd) A B7-H3 ANTIBODY DRUG CONJUGATE (ADC) VERSUS TREATMENT OF PHYSICIAN'S CHOICE (TPC) IN SUBJECTS WITH RELAPSED SMALL CELL LUNG CANCER (SCLC) (IDeate-Lung02) (DS7300-188)
